Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy[1] Bezafibrate[1] Bezafibrate 💬 [1] PPARA 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 94 💬
2Bezafibrate 200 mg in addition to UDCA therapy[1] Bezafibrate[1] Bezafibrate 💬 [1] PPARA 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬
3Bezafibrate 400 mg in addition to UDCA therapy[1] Bezafibrate[1] Bezafibrate 💬 [1] PPARA 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬
4Standard of Care: UDCA----[1] 93 💬
5UDCA----[2] 93, 94 💬
6UDCA (Ursodeoxycholic acid)[1] Ursodeoxycholic acid (UDCA)[1] Ursodiol 💬 [1] NR1H4 💬 [1] Bile secretion 💬[1] 93 💬
7Ursodeoxycholic acid (UDCA)[1] Ursodeoxycholic acid (UDCA)[1] Ursodiol 💬 [1] NR1H4 💬 [1] Bile secretion 💬[1] 94 💬
8Ursodeoxycholic acid (UDCA) 500 mg[1] Ursodeoxycholic acid (UDCA)[1] Ursodiol 💬 [1] NR1H4 💬 [1] Bile secretion 💬[1] 46 💬
9Ursodiol (ursodeoxycholic acid, UDCA)[1] Ursodeoxycholic acid (UDCA)[1] Ursodiol 💬 [1] NR1H4 💬 [1] Bile secretion 💬[1] 97 💬